Tumor SUVmax Normalized to Liver Uptake on 18F-FDG PET/CT Predicts the Pathologic Complete Response After Neoadjuvant Chemoradiotherapy in Locally Advanced Rectal Cancer

被引：36

作者：

Park J. ^{[1
]}

Chang K.J. ^{[1
]}

Seo Y.S. ^{[2
]}

Byun B.H. ^{[1
]}

Choi J.H. ^{[1
]}

Moon H. ^{[1
]}

Lim I. ^{[1
]}

Kim B.I. ^{[1
]}

Choi C.W. ^{[1
]}

Lim S.M. ^{[1
]}

机构：

[1] Department of Nuclear Medicine, Korea Cancer Center Hospital, 75, Nowon-ro, Nowon-gu, Seoul

[2] Department of Radiation Oncology, Korea Cancer Center Hospital, 75, Nowon-ro, Nowon-gu, Seoul

来源：

Nuclear Medicine and Molecular Imaging | 2014年 / 48卷 / 4期

关键词：

!sup]18[!/sup]F-FDG; Chemoradiotherapy; Positron emission tomography; Rectal Cancer; Response;

D O I：

10.1007/s13139-014-0289-x

中图分类号：

学科分类号：

摘要：

Purpose: This study investigates the feasibility of using 18F-fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG PET/CT) to predict the pCR (pathologic complete response) rate after neoadjuvant chemoradiotherapy (NCRT) in patients with locally advanced rectal cancer.; Methods: A total of 88 patients with locally advanced rectal cancer were retrospectively analyzed. All patients were treated with NCRT, followed by radical surgery, and 18F-FDG PET/CT was performed before and after NCRT. For a semiquantitative assessment, a volume of interest was drawn, including the whole tumor region, and the maximum SUV (SUVmax), SUVmax normalized to liver uptake (SLR), SUVmax normalized to blood pool uptake (SBR), the metabolic tumor volume at SUV 2.0 (MTV[2.0]), SUV 2.5 (MTV[2.5]), and SUV 3.0 (MTV[3.0]) were measured. In addition, their percentage changes after NCRT were assessed. The pCR was verified through a histologic examination of postsurgical specimens. A receiver operating characteristic curve analysis was conducted to predict the pCR by using these PET parameters.; Conclusions: F-FDG PET was found to be useful for predicting the pCR after NCRT in patients with locally advanced rectal cancer. Among various PET parameters, SUVmax normalized to liver uptake after NCRT was the best predictor of the pCR.; Results: The pCR was predicted in 17 patients (19 ). The values of the area under the curve (AUC) for predicting the pCR were 0.774 for SUVmax after NCRT, 0.826 for SLR after NCRT, 0.815 for SBR after NCRT, 0.724 for MTV(2.5) after NCRT, 0.729 for the percentage change in SUVmax, 0.700 for the percentage change in SLR, and 0.749 for the percentage change in MTV (2.5). Among these PET parameters, SLR after NCRT showed the highest AUC value. The optimal criterion, sensitivity, specificity, and accuracy of SLR after NCRT for predicting the pCR were ≤1.41, 88 %, 65 %, and 68 %, respectively. © 2014, Korean Society of Nuclear Medicine.

引用

页码：295 / 302

页数：7

共 54 条

[1]

Shin A., Kim K.Z., Jung K.W., Park S., Won Y.J., Kim J., Et al., Increasing trend of colorectal cancer incidence in Korea, 1999–2009, Cancer Res Treat, 44, 4, pp. 219-226, (2012)

[2]

Jung K.W., Won Y.J., Kong H.J., Oh C.M., Seo H.G., Lee J.S., Cancer statistics in Korea: Incidence, mortality, survival and prevalence in 2010, Cancer Res Treat, 45, 1, pp. 1-14, (2013)

[3]

Valentini V., Coco C., Cellini N., Picciocchi A., Fares M.C., Rosetto M.E., Et al., Ten years of preoperative chemoradiation for extraperitoneal T3 rectal cancer: acute toxicity, tumor response, and sphincter preservation in three consecutive studies, Int J Radiat Oncol Biol Phys, 51, 2, pp. 371-383, (2001)

[4]

Sauer R., Becker H., Hohenberger W., Rodel C., Wittekind C., Fietkau R., Et al., Preoperative versus postoperative chemoradiotherapy for rectal cancer, N Engl J Med, 351, 17, pp. 1731-1740, (2004)

[5]

Eich H.T., Stepien A., Zimmermann C., Hellmich M., Metzger R., Holscher A., Et al., Neoadjuvant radiochemotherapy and surgery for advanced rectal cancer: prognostic significance of tumor regression, Strahlenther Onkol, 187, 4, pp. 225-230, (2011)

[6]

Martin S.T., Heneghan H.M., Winter D.C., Systematic review and meta-analysis of outcomes following pathological complete response to neoadjuvant chemoradiotherapy for rectal cancer, Br J Surg, 99, 7, pp. 918-928, (2012)

[7]

Janssen M.H., Ollers M.C., Riedl R.G., van den Bogaard J., Buijsen J., van Stiphout R.G., Et al., Accurate prediction of pathological rectal tumor response after two weeks of preoperative radiochemotherapy using (18)F-fluorodeoxyglucose-positron emission tomography-computed tomography imaging, Int J Radiat Oncol Biol Phys, 77, 2, pp. 392-399, (2010)

[8]

van Stiphout R.G., Lammering G., Buijsen J., Janssen M.H., Gambacorta M.A., Slagmolen P., Et al., Development and external validation of a predictive model for pathological complete response of rectal cancer patients including sequential PET-CT imaging, Radiother Oncol, 98, 1, pp. 126-133, (2011)

[9]

Habr-Gama A., Perez R.O., Nadalin W., Sabbaga J., Ribeiro U., Silva e Sousa A.H., Et al., Operative versus nonoperative treatment for stage 0 distal rectal cancer following chemoradiation therapy: long-term results, Ann Surg, 240, 4, pp. 711-717, (2004)

[10]

Schmoll H.J., Van Cutsem E., Stein A., Valentini V., Glimelius B., Haustermans K., Et al., ESMO Consensus Guidelines for management of patients with colon and rectal cancer. A personalized approach to clinical decision making, Ann Oncol, 23, 10, pp. 2479-2516, (2012)

← 1 2 3 4 5 6 →